The present invention relates to a novel compound that enables formation of an additional hydrogen bond with a specific amino acid position in histone acetyltransferase (HAT) p300 through the structural analysis of the HAT p300. The novel compound of the present invention has a significantly excellent inhibitory effect on the activity of HAT p300 and can be used very effectively in the prevention, amelioration or treatment of diseases associated with the activation of HAT p300, such as fibrosis.

The present invention relates to a novel compound that enables formation of an additional hydrogen bond with a specific amino acid position in histone acetyltransferase (HAT) p300 through the structural analysis of the HAT p300. The novel compound of the present invention has a significantly excellent inhibitory effect on the activity of HAT p300 and can be used very effectively in the prevention, amelioration or treatment of diseases associated with the activation of HAT p300, such as fibrosis.

Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

Provided are: a trisubstituted benzene compound represented by general formulae (1) and (2); and an organic electroluminescence (EL) element having a pair of electrodes and at least a pair of organic layers interposed therebetween, the organic EL element being characterized in that said compound is used as a constituent material for at least one organic layer.

##STR00001##

The present application relates to fluorinated benzylsulfonamide hydroxamic acid compounds of Formula I and/or pharmaceutically acceptable salt, solvate and/or prodrug thereof: (I) for use as a inhibitor of HDAC6. The application also relates to methods of treating a disease, disorder or condition using the compounds and compositions of the application.

##STR00001##

The present application relates to fluorinated benzylsulfonamide hydroxamic acid compounds of Formula I and/or pharmaceutically acceptable salt, solvate and/or prodrug thereof: (I) for use as a inhibitor of HDAC6. The application also relates to methods of treating a disease, disorder or condition using the compounds and compositions of the application.

##STR00001##

The present invention relates to oxocarbon-, pseudooxocarbon- and radialene compounds as well as to their use as doping agent for doping an organic semiconductive matrix material, as blocker material, as charge injection layer, as electrode material as well as organic semiconductor, as well as electronic components and organic semiconductive materials using them.

The present invention relates to oxocarbon-, pseudooxocarbon- and radialene compounds as well as to their use as doping agent for doping an organic semiconductive matrix material, as blocker material, as charge injection layer, as electrode material as well as organic semiconductor, as well as electronic components and organic semiconductive materials using them.

The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof. ##STR00001##